1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • December 2016
  • 213 pages
  • ID: 4794298
  • Format: PDF
  • GlobalData


Table of Contents

Search Inside

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025


Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid hormone (PTH) stemming from overactivity of the parathyroid glands. The parathyroid glands, of which there are four, regulate physiological calcium homeostasis through a negative feedback mechanism involving PTH secretion. HPT is classified into either primary, secondary, or tertiary, and it is important to differentiate between the three as their underlying aetiology, pathology, and treatment differ.

Sales of hyperparathyroidism (HPT) therapeutics is estimated to be approximately $6.69B in 2015 across the seven major markets covered in this report (7MM): the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year, 92% of market share was attributed to secondary HPT (SHPT) therapy sales ($6.16B), whereas primary HPT (PHPT) and tertiary HPT (THPT) held just 4.5% ($307M) and 3.5% ($225M) of the market, respectively.

The most notable trend in corporate strategy in the hyperparathyroidism space was the attempt to develop drugs without the adverse effects seen with the available drug classes. This led to the introduction of cornerstone therapies: Sanofi/Genzyme’s first non-metal based phosphate binders, Renvela/Renagel (sevelamer hydrochloride/carbonate), and AbbVie’s first selective vitamin D receptor agonist (VDRA), Zemplar (paricalcitol), both of which did not cause the associated hypercalcemia seen with the previous standard of care (SOC). Corporate strategy at present follows a similar trend, being particularly gauged towards improving compliance with existing drug classes by enhancing their safety, tolerability, and/or efficacy profiles.

By 2025, it is expected that the HPT market will grow at a strong Compound Annual Growth Rate (CAGR) of 1.8%, reaching sales of $8.04B by the end of the forecast period. This is mainly attributed to growth in the SHPT space, which is forecast to reflect a CAGR of 2.2%, reaching $7.68B in sales by 2025 (96% of market share). In general, the US will contribute the most to the HPT market growth, as it is predicted to grow at a CAGR of 2.4%, from $3.97B in 2015 to $5.04B in 2025.

Major drivers of HPT market growth over the forecast period are the -
- Launch of Amgen’s first intravenous (IV) calcimimetic, Parsabiv (etelcalcetide), in all 7MM throughout 2017
- Increase in the global prevalence of HPT
- Launch of Rayaldee (calcifediol ER) in the US in 2016
- Increased use of new iron-based phosphate binders, Velphoro (sucroferric oxyhydroxide) and Auryxia (ferric citrate)

Companies mentioned in this report: Amgen, Shire, Shield Therapeutics, Keryx Biopharmaceuticals, Sanofi/Genzyme, Vifor Pharmaceuticals, OPKO Health, Inc., Deltanoid Pharmaceuticals, Ardelyx, Spectrum Pharmaceuticals.

- Overview of HPT, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HPT therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HPT therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HPT therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HPT therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HPT therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HPT therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021

  • $ 3500
  • June 2021
  • 60 pages

N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021 Summary According to the recently published report ’N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021’; N Sulphoglucosamine ...

  • World
  • Pharmaceutical
  • Therapy
  • Industry analysis
  • Medical Technology Density
  • Pharmaceutical Exports


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on